BMJ. 1998 Sep 12;317(7160):703-13.
To determine whether tight control of blood pressure prevents macrovascular and microvascular complications in patients with type 2 diabetes.
Randomised controlled trial comparing tight control of blood pressure aiming at a blood pressure of <150/85 mm Hg (with the use of an angiotensin converting enzyme inhibitor captopril or a beta blocker atenolol as main treatment) with less tight control aiming at a blood pressure of <180/105 mm Hg.
20 hospital based clinics in England, Scotland, and Northern Ireland.
1148 hypertensive patients with type 2 diabetes (mean age 56, mean blood pressure at entry 160/94 mm Hg); 758 patients were allocated to tight control of blood pressure and 390 patients to less tight control with a median follow up of 8.4 years.
Predefined clinical end points, fatal and non-fatal, related to diabetes, deaths related to diabetes, and all cause mortality. Surrogate measures of microvascular disease included urinary albumin excretion and retinal photography.
Mean blood pressure during follow up was significantly reduced in the group assigned tight blood pressure control (144/82 mm Hg) compared with the group assigned to less tight control (154/87 mm Hg) (P<0.0001). Reductions in risk in the group assigned to tight control compared with that assigned to less tight control were 24% in diabetes related end points (95% confidence interval 8% to 38%) (P=0.0046), 32% in deaths related to diabetes (6% to 51%) (P=0.019), 44% in strokes (11% to 65%) (P=0.013), and 37% in microvascular end points (11% to 56%) (P=0.0092), predominantly owing to a reduced risk of retinal photocoagulation. There was a non-significant reduction in all cause mortality. After nine years of follow up the group assigned to tight blood pressure control also had a 34% reduction in risk in the proportion of patients with deterioration of retinopathy by two steps (99% confidence interval 11% to 50%) (P=0.0004) and a 47% reduced risk (7% to 70%) (P=0.004) of deterioration in visual acuity by three lines of the early treatment of diabetic retinopathy study (ETDRS) chart. After nine years of follow up 29% of patients in the group assigned to tight control required three or more treatments to lower blood pressure to achieve target blood pressures.
Tight blood pressure control in patients with hypertension and type 2 diabetes achieves a clinically important reduction in the risk of deaths related to diabetes, complications related to diabetes, progression of diabetic retinopathy, and deterioration in visual acuity.
确定严格控制血压是否能预防2型糖尿病患者的大血管和微血管并发症。
随机对照试验,比较旨在将血压控制在<150/85 mmHg(主要使用血管紧张素转换酶抑制剂卡托普利或β受体阻滞剂阿替洛尔进行治疗)的严格血压控制与旨在将血压控制在<180/105 mmHg的较宽松血压控制。
英格兰、苏格兰和北爱尔兰的20家医院门诊。
1148例2型糖尿病高血压患者(平均年龄56岁,入组时平均血压160/94 mmHg);758例患者被分配至严格血压控制组,390例患者被分配至较宽松血压控制组,中位随访时间为8.4年。
与糖尿病相关的预定义临床终点,包括致命性和非致命性终点、糖尿病相关死亡以及全因死亡率。微血管疾病的替代指标包括尿白蛋白排泄和视网膜照相。
与较宽松血压控制组(154/87 mmHg)相比,严格血压控制组随访期间的平均血压显著降低(144/82 mmHg)(P<0.0001)。与较宽松血压控制组相比,严格控制组在糖尿病相关终点的风险降低了24%(95%置信区间8%至38%)(P=0.0046),在糖尿病相关死亡方面降低了32%(6%至51%)(P=0.019),在中风方面降低了44%(11%至65%)(P=0.013),在微血管终点方面降低了37%(11%至56%)(P=0.0092),主要是由于视网膜光凝风险降低。全因死亡率有非显著性降低。随访9年后,严格血压控制组中视网膜病变恶化两级的患者比例风险降低了34%(99%置信区间11%至50%)(P=0.0004),糖尿病视网膜病变早期治疗研究(ETDRS)图表中视力下降三级的风险降低了47%(7%至70%)(P=0.004)。随访9年后,严格控制组中有29%的患者需要三种或更多治疗来降低血压以达到目标血压。
高血压合并2型糖尿病患者严格控制血压可使糖尿病相关死亡、糖尿病相关并发症、糖尿病视网膜病变进展和视力下降的风险在临床上显著降低。